As VEGF-C and –D exert their biological effects mainly via the VEGFR-3-pathway in addition to VEGF-A, multikinase inhibitors may have the potential to be used as specific antiangiogenic drug for tumours with high VEGF-C- levels at high risk for retroperitoneal metastases. This evidence concerns the gene VEGFA and neoplasm.